There are numerous evidenced based treatments for psychiatric disorders, using pharmacological and psychotherapeutic approaches. Predicting which of these therapies will work for any given individual remains as much an art as a science, resulting in therapeutic delays, needless costs, and human suffering. A new era of personalized medicine tailored to the patient's unique biomarkers to specify treatment choices is beginning to emerge throughout medicine and in psychiatry.
The 2014 APPA annual meeting brings together experts to describe the most promising biomarkers, which may form the basis for future personalized treatment. Scientists who are carrying out therapeutic trials testing biomarkers alone or in combination to treat individuals with depression, anxiety disorders, schizophrenia or addiction, will also describe their most recent and salient findings.